MRA and ARB Treatment in Screening of Primary Aldosteronism

NCT04185857 · clinicaltrials.gov ↗

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Primary Aldosteronism Due to Aldosterone Producing Adenoma

Interventions

DRUG: canrenone 50-100 mg orally once a day
DRUG: olmesartan 10-20 mg orally once a day

Sponsor

University Hospital Padova